Acute Myeloid Leukemia Clinical Trial
— BusulfanOfficial title:
A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan and Bolus Etoposide as Preparative Therapy for Patients With Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation
Verified date | August 2017 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Busulfan and etoposide have been used as preparative therapy for autoSCT (stem cell
transplant) in adults with acute myeloid leukemia (AML) at UCSF for the past 10 years. Over
this period and together with collaborative transplant centers, over 200 patients have
received this treatment. By intent-to-treat analysis, and with median follow-up of 7.0 years,
the 5-year DFS is 55%. The current protocol will utilize the combination of IV Busulfan (BU)
and etoposide. The busulfan dose will be escalated amongst 3 targeted dose levels. All
targeted dose levels represent higher busulfan dosing than standard myeloablative dosing,
with the lowest dose being approximately 14% higher than standard. Busulfan levels will be
monitored after the first, fourth and twelfth doses. Dose adjustments will be made "in real
time" based on AUC levels determined from the first and fourth doses. This strategy of
busulfan monitoring and dose adjustment has improved the therapeutic widow of BU in previous
clinical trials.
The current protocol will utilize the combination of intravenous busulfan and etoposide. The
busulfan dose will be escalated amongst 3 targeted dose levels (area under the curve (AUC)
levels at time 6 hours of 1250 uMol*min, 1400 uMol*min and 1550 uMol*min). All targeted dose
levels represent higher busulfan dosing than standard myeloablative dosing with the lowest
dose (1250 uMol*min) being approximately 14% higher than standard. In the absence of
dose-limiting toxicity, cohorts of 4-6 patients will be treated at each dose level and 10
additional patients will be treated at the maximum tolerated dose (MTD) to confirm safety.
The busulfan dosing will begin at 1 mg/kg based on historical plasma levels obtained from
patients receiving BU at a starting dose of 0.8 mg/kg at UCSF Medical Center.
The highest dose level proposed for this study will exceed the reported toxic level for
busulfan in the alloSCT setting. Patients will be followed closely for toxicity and strict
stopping rules have been included. Eligibility criteria will exclude patients with prior
history of hepatotoxicity or viral hepatitis. Potential hepatotoxic agents will not be
allowed just prior to and during the busulfan dosing period. In addition, patients who
experience hepatotoxicty during pre-transplant mobilization therapy may be excluded from
receiving dose-escalated busulfan therapy. Every attempt will be made to prevent or avoid
hepatotoxicity.
Status | Completed |
Enrollment | 12 |
Est. completion date | February 25, 2015 |
Est. primary completion date | December 31, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 69 Years |
Eligibility |
Inclusion Criteria: Before Consolidation Chemotherapy - Age 18-69 years - Diagnosis of AML - CR with =2 courses of induction chemotherapy. - Out of the hospital for a minimum of 4 weeks from induction chemotherapy or 3 weeks if consolidation chemotherapy has been administered. - Remission bone marrow bx w/i 2 wks of beginning post remission rx. - One cycle of post-remission consolidation w/standard dose cytarabine or HDAC with <8 doses of HDAC. - Benign CSF: Lumbar puncture with cell count, differential and protein to determine lack of extramedullary leukemia required w/i 2 weeks of post- remission therapy IF CSF status is unknown or has been positive at dx. - No active infection - No evidence of prior liver disease. - Creatinine <2.0 mg/dl. - Cardiac ejection fraction =40%. - Adequate pulmonary function with DLCO =40% of predicted. - No co-morbid medical condition that would jeopardize the chance of tolerating aggressive chemotherapy. - ECOG 0-2 - Signed informed consent. Eligibility to be Re-assessed Before Autologous SCT - Minimum of 4 weeks out of hospital after post-remission rx. - Continued CR documented by bone marrow morphology and cytogenetics (if previously abnormal), performed within 2 wks of admission for autologous transplantation. - Adequate marrow recovery from post-remission therapy as demonstrated by an ANC = 500/µl, platelets = 50,000/µl and stable or improving hemoglobin (transfusion independent). - Adequate peripheral stem cells collected and stored; - No evidence of liver dysfunction as determined within 2 weeks of transplant admission. Bilirubin must be < 2.0 mg/dl and the AST and alkaline phosphatase < 3x the upper limit of normal. - Creatinine < 2.0 mg/dl. - No active infection or need for ongoing antibiotics. |
Country | Name | City | State |
---|---|---|---|
United States | University of California Med. Center | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | to determine MTD amongst 3 targeted dose levels of IV busulfan given with etoposide as prep therapy in pts with AML undergoing autologous stem cell transplantation. Safety is the primary goal. | 3 yrs | ||
Secondary | To achieve targeted busulfan levels following dose-adjustment of approximately (+/-) 10% in >80% of patients (i.e. target=1250 uMol*min, acceptable range 1125-1375 uMol*min, target=1400 uMol*min, acceptable range 1260-1540 ng/ml, etc) | 3 yrs |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |